Podcast

In this edition, immunotherapy improves survival rates of infants with leukemia; extreme poverty linked to higher risk for relapse among children with ALL; FDA approves allogeneic cell therapy and more.

In this edition, trichloroethylene may be ‘invisible’ cause of PD, ravulizumab reduces clinical deterioration in generalized myasthenia gravis and more.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the new leadership at STAAR Surgical with Tom Frinzi, president and CEO; Warren Foust, COO; and Magda Michna, PhD.

In this edition, elevated cardiotoxicity risk for Black patients after chemotherapy; CV risk factor disparities in childhood cancer survivors; neural network helps identify potential targets for cancer drugs and more.

In this episode, host Shikha Jain, MD, speaks with CureMatch CEO Navid Alipour about the rise of AI in the health care space, how technology can elevate the ways in which we diagnose and deliver health care and more.

In this edition, DNA sequencing could identify patients with high-risk AML; review of major advances and challenges in chronic lymphocytic leukemia; FDA advisory panel backs polatuzumab vedotin and more.

In this edition, ‘paradigm shift’ in non-small cell lung cancer during past decade; osimertinib extends survival in early EGFR-mutated NSCLC; amivantamab shows durable activity in patients with advanced NSCLC, and more.

In this episode, host Shikha Jain, MD, speaks with Jorge García, PharmD, about the economic benefits of biosimilars, the unique perspective pharmacists bring to cancer care costs and more.

In this edition, optimal antibiotics timing among inpatients with cancer; inflammation levels linked to survival in acute myeloid leukemia; dexrazoxane confers long-term cardioprotection for pediatric cancer and more.

Cathleen M. McCabe, MD, and Laura M. Periman, MD, chat with Marguerite McDonald, MD, FACS, about meeting expectations and how to handle the pressure of trials and tribulations.